clinical trial · NCT06052566
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
Merck Sharp & Dohme LLC·phase1·completed·n = 22
Non-alcoholic SteatohepatitisHepatic ImpairmentEfinopegdutide
brief summary
The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
started
Nov 21, 2023
primary completion
Dec 5, 2024
completion
Dec 5, 2024
last updated
Oct 22, 2025
official title
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol